The FTC has paused its antitrust case against major PBMs, citing a lack of commissioners. The lawsuit alleges unfair ...
They are mistaken about the identity of Zelis’s clients, the operation of Zelis’s solutions, and the benefits Zelis provides ...
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback